Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plitidepsin Extension Study in Post-COVID Patients
NCT05121740Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of plitidepsin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by PharmaMar. Primary endpoint: Number and Percentage of Participants With Complications Related to Post COVID-19 Infection at 12 months. Started Jan 2022; status: completed.
02
Drugs
plitidepsin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05121740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121740.